← All trials
NCT00668759
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2008
- Primary completion
- Oct 1, 2009
- Completion date
- Nov 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 254
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Cardiome PharmaLead sponsor
- Universitetssjukhuset MASOverall official - principal investigator
- University of TartuOverall official - principal investigator
- University of OuluOverall official - principal investigator
- University of LorraineOverall official - principal investigator
- Samodzielny Publiczny SzpitalOverall official - principal investigator
- University of CopenhagenOverall official - principal investigator
- J. W. Goethe UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.